June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation Improves Multisensory Integration in Open-Angle Glaucoma.
Author Affiliations & Notes
  • Ekaterina Loskutova
    Centre for Eye Research Ireland (CERI), Technological University Dublin, Dublin, Dublin, Ireland
  • John S Butler
    Centre for Eye Research Ireland (CERI), Technological University Dublin, Dublin, Dublin, Ireland
  • Annalisa Setti
    School of Applied Psychology, University College Cork, Cork, Cork, Ireland
  • Gareth Lingham
    Centre for Eye Research Ireland (CERI), Technological University Dublin, Dublin, Dublin, Ireland
  • Colm J O'Brien
    Department of Ophthalmology, Mater Misericordiae University Hospital, Dublin, Ireland
  • James Loughman
    Centre for Eye Research Ireland (CERI), Technological University Dublin, Dublin, Dublin, Ireland
  • Footnotes
    Commercial Relationships   Ekaterina Loskutova None; John Butler None; Annalisa Setti None; Gareth Lingham None; Colm O'Brien None; James Loughman None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3881 – A0083. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ekaterina Loskutova, John S Butler, Annalisa Setti, Gareth Lingham, Colm J O'Brien, James Loughman; Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation Improves Multisensory Integration in Open-Angle Glaucoma.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3881 – A0083.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the effect of supplementation with Lutein (L), Zeaxanthin (Z) and Meso-Zeaxanthin (MZ) on multisensory integration (MSI) performance among individuals with open-angle glaucoma (OAG).

Methods : The European Nutrition in Glaucoma Management study (ENIGMA, ClinicalTrials.gov id: NCT04460365) is a placebo-controlled, double-masked randomized trial evaluating the effects of 18 months of carotenoid supplementation in OAG. 62 participants (24 female) with a diagnosis of OAG were enrolled, of whom 42 were randomized to active treatment (10 mg L, 10 mg MZ, 2 mg Z [MacuShield®]), and 20 to placebo. Macular pigment optical density (MPOD) was measured in the study eye using dual-wavelength autofluorescence (Heidelberg Spectralis OCT). MSI was assessed using the sound induced flash illusion (SIFI), where participants indicated the number of visual flashes observed on screen, while simultaneously presented with a congruent or incongruent number of auditory beeps. Participants susceptibility to the SIFI illusion, where individuals misperceive the number of flashes displayed in the incongruent condition, was assessed as an indicator of MSI efficiency.

Results : Mean MPOD increased by 60% in treated participants over the study duration, indicating effective carotenoid tissue deposition. A 2 (treatment: active and placebo) by 2 (time: baseline and 18 months) mixed repeated-measures ANOVA revealed a statistically significant interaction of treatment and time (F (1,48) = 4.518, p = 0.039) for the incongruent SIFI condition, indicating improved MSI performance following supplementation in those treated with carotenoids, but not placebo.

Conclusions : MSI performance improved significantly in response to supplementation with L, Z and MZ in people with OAG. MSI deficiencies have been reported in older individuals prone to falling, an issue known to affect people living with glaucoma. This finding indicates that MSI performance, a factor potentially linked to daily life issues affecting people with glaucoma such as risk of falls, driving safety concerns and general impact on quality of life, may be improved by supplementation with a mix of L, Z and MZ carotenoids.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Figure 1. Accuracy on SIFI task, represented as the proportion of correct responses across the different stimulus onset asynchronies (SOA)s trials. Error bars indicate ± 1 standard error of the mean.

Figure 1. Accuracy on SIFI task, represented as the proportion of correct responses across the different stimulus onset asynchronies (SOA)s trials. Error bars indicate ± 1 standard error of the mean.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×